Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India Speed-Up For Phase I Trial Approvals Draws Criticism

This article was originally published in PharmAsia News

Executive Summary

India's effort to step up its approval process for Phase I trials has drawn warnings from critics that the lack of expertise could be a problem. Currently, India allows only drug makers who have developed their drugs in the country to conduct early-stage trials. The government is trying to reduce its approval time for those trials, drawing criticism from some experts. The Indian drug industry is pressuring the government to reduce its approval time to 30 days, similar to the practice in Western countries. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts